Time to redefine a primary vaccination series?

Affiliations

¹ Department of Internal Medicine, Hacettepe University School of Medicine, Ankara o6230, Turkey; Hacettepe University Vaccine Institute, Ankara, Turkey. Electronic address: mdurusu@yahoo.com.
² Department of Clinical Microbiology and Infectious Diseases, Hacettepe University School of Medicine, Ankara o6230, Turkey; Hacettepe University Vaccine Institute, Ankara, Turkey.

Comment

Mine Durusu Tanriover et al. Lancet Infect Dis. 2022 Dec.

. 2022 Dec;22(12):1654-1655.

doi: 10.1016/S1473-3099(22)00576-X. Epub 2022 Sep 13.

¹ Department of Internal Medicine, Hacettepe University School of Medicine, Ankara o6230, Turkey; Hacettepe University Vaccine Institute, Ankara, Turkey. Electronic address: mdurusu@yahoo.com.
² Department of Clinical Microbiology and Infectious Diseases, Hacettepe University School of Medicine, Ankara o6230, Turkey; Hacettepe University Vaccine Institute, Ankara, Turkey.

No abstract available

Conflict of interest statement

We declare no competing interests.

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Hardt K, Vandebosch A, Sadoff J, Le Gars M, Truyers C, Lowson D, Van Dromme I, Vingerhoets J, Kamphuis T, Scheper G, Ruiz-Guiñazú J, Faust SN, Spinner CD, Schuitemaker H, Van Hoof J, Douoguih M, Struyf F; ENSEMBLE2 study group. Hardt K, et al. Lancet Infect Dis. 2022 Dec;22(12):1703-1715. doi: 10.1016/S1473-3099(22)00506-0. Epub 2022 Sep 13. Lancet Infect Dis. 2022. PMID: 36113538 Free PMC article. Clinical Trial.

1. Munro APS, Feng S, Janani L, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis. 2022;22:1131–1141. - PMC - PubMed
1. Our World in Data Share of people who received at least one dose of COVID-19 vaccine. https://ourworldindata.org/grapher/share-people-vaccinated-covid?country...
1. Hardt K, Vandebosch A, Sadoff J, et al. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2022 doi: 10.1016/S1473-3099(22)00506-0. published online Sept 13. - DOI - PMC - PubMed
1. Sadoff J, Gray G, Vandebosch A, et al. Final analysis of efficacy and safety of single-dose Ad26.COV2.S. N Engl J Med. 2022;386:847–860. - PMC - PubMed
1. Gray G, Collie S, Goga A, et al. Effectiveness of Ad26.COV2.S and BNT162b2 vaccines against omicron variant in South Africa. N Engl J Med. 2022;386:2243–2245. - PMC - PubMed